Brainsway Ltd (BWAY) stock: key figures, P/E, revenue and dividend

Health Care · Health Care Equipment · United States · ISIN US10501L1061

Price
11.93 USD
Market cap
480.22 m USD
P/E (2025)
33.14
P/S (2025)
9.20
Dividend yield
0.00 %
Net margin
14.62 %
Return on equity (ROE)
10.42 %
Return on assets (ROA)
6.76 %

Brainsway Ltd financials

Fiscal year20242025
Revenue41.02 m USD52.23 m USD
Gross profit30.58 m USD39.39 m USD
Operating income1.39 m USD4.32 m USD
EBIT3.59 m USD9.92 m USD
Net income2.92 m USD7.63 m USD
Diluted EPS – continuing operations0.08 USD0.36 USD

Full history since 2000, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Brainsway Ltd

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.